oncology
Breast Cancer

Is it time to curb overuse of neoadjuvant chemotherapy?

Neoadjuvant chemotherapy has come into widespread use in breast cancer based on a flawed rationale and it is now time to limit its use, UK oncologists say. In an article in The BMJ, a group of UK-based oncologists say the dramatic shrinkage of primary tumours seen with neoadjuvant chemotherapy does not translate into survival benefits ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic